PATENT CLAIM ANALYSIS

Application Number: 16033764
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["514", "236500"]

Abstract:
The use of compounds of formula (I) in the treatment of Epidermal Growth Factor Receptor (EGFR) dependent diseases or diseases that have acquired resistance to agents that target EGFR family members, use of said compounds for the manufacture of pharmaceutical compositions for the treatment of said diseases, combinations of said compounds with EGFR modulators for said use, methods of treating said diseases with said compounds and pharmaceutical preparations for the treatment of said diseases comprising said compounds alone or in combination, especially with an EGFR modulator.

Claim (Index 6):
The method according to  claim 1 , wherein the disease to be treated is a malignancy.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 95.0
- Lexical Diversity: 1.97917
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14645578', '15110685', '15435722', '13302409', '13109670']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6886137432875306
- 35 USC 102 Novelty (BERT): 0.5292105714080511
- Combined Prediction Score: 0.6726734260995826
- Mean Citation Score: 292.439094
- Max Citation Score: 305.87045
- Similarity Product: 202.1971807919681

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test